NanoGhost Overview
- Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$5M
- Investors
-
1
NanoGhost General Information
Description
Developer of a drug-delivery technology intended to shrink the deadliest forms of cancer by precisely targeting tumors. The company's technology uses adult stem cells to transport medicine directly to the tumor site that aids in reducing tumor size in small lung carcinoma, prostate, and pancreatic cancer tumors, enabling patients suffering from cancer to reduce the pain of radiology treatments.
Contact Information
Website
www.nano-ghost.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Primary Office
- 12 Beni Gaon Street
- Post Office Box 8936
- Netanya
- Israel
NanoGhost Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 23-Dec-2019 | $5M | 000 | 000.00 | Completed | Pre-Clinical Trials |
NanoGhost Executive Team (3)
NanoGhost Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Marcelle Machluf Ph.D | NanoGhost | Founder, Director & Board Member | 000 0000 |
| Osnat Kashtan | NanoGhost | Vice President of Research & Development & Board Member | 000 0000 |
| Yonatan Malca | Self | Chief Executive Officer & Board Member | 000 0000 |
NanoGhost Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| aMoon Fund | Venture Capital | Minority | 000 0000 | 000000 0 |